既往HPV阴性组中新发HPV感染的发生率与使用不同避孕方法有关：一项回顾性队列研究

IF 2.8 2区医学 Q3 IMMUNOLOGY

Infectious Agents and Cancer Pub Date : 2025-08-05 DOI:10.1186/s13027-025-00688-6

Lina Jans, Jan Brynhildsen, Joar Hofgaard, Safia Ansari, Lovisa Eklöf, Lovisa Bergengren

{"title":"既往HPV阴性组中新发HPV感染的发生率与使用不同避孕方法有关：一项回顾性队列研究","authors":"Lina Jans, Jan Brynhildsen, Joar Hofgaard, Safia Ansari, Lovisa Eklöf, Lovisa Bergengren","doi":"10.1186/s13027-025-00688-6","DOIUrl":null,"url":null,"abstract":"Background: Users of intrauterine devices (IUDs) have been found to have a lower incidence of cervical cancer in meta-analyses, but these studies have not been able to examine the influence of IUD type. The aim of this study is to investigate the incidence of de novo high-risk human papillomavirus (HPV) infections in relation to the reported use of contraceptive methods, with special regard to different types of IUDs.Methods: A sample of participants in the national screening program for cervical cancer (n = 11,702) with a negative HPV test in 2017-2018 were included. Their subsequent HPV test results in 2020-2023 were analyzed in relation to their reported contraceptive method.Results: Participants who reported use of hormonal contraception had higher incidence of a positive HPV screening test (5.6%) compared with women with no reported contraception (4.2%) (OR 1.29; 95% CI 1.01-1.64). There was no significant difference in HPV incidence among women who reported use of hormonal IUD (HIUD) or copper-containing IUD (CU-IUD). Women who reported use of the same contraceptive method in both screening rounds showed no significant differences in HPV incidence, regardless of the contraceptive method they had used.Conclusion: The incidence of de novo HPV infections is not significantly different in users of different types of IUD.","PeriodicalId":13568,"journal":{"name":"Infectious Agents and Cancer","volume":"20 1","pages":"54"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12326846/pdf/","citationCount":"0","resultStr":"{\"title\":\"Incidence of de novo HPV infections in a previous HPV-negative group, related to use of different contraceptive methods: a retrospective cohort study.\",\"authors\":\"Lina Jans, Jan Brynhildsen, Joar Hofgaard, Safia Ansari, Lovisa Eklöf, Lovisa Bergengren\",\"doi\":\"10.1186/s13027-025-00688-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Users of intrauterine devices (IUDs) have been found to have a lower incidence of cervical cancer in meta-analyses, but these studies have not been able to examine the influence of IUD type. The aim of this study is to investigate the incidence of de novo high-risk human papillomavirus (HPV) infections in relation to the reported use of contraceptive methods, with special regard to different types of IUDs.Methods: A sample of participants in the national screening program for cervical cancer (n = 11,702) with a negative HPV test in 2017-2018 were included. Their subsequent HPV test results in 2020-2023 were analyzed in relation to their reported contraceptive method.Results: Participants who reported use of hormonal contraception had higher incidence of a positive HPV screening test (5.6%) compared with women with no reported contraception (4.2%) (OR 1.29; 95% CI 1.01-1.64). There was no significant difference in HPV incidence among women who reported use of hormonal IUD (HIUD) or copper-containing IUD (CU-IUD). Women who reported use of the same contraceptive method in both screening rounds showed no significant differences in HPV incidence, regardless of the contraceptive method they had used.Conclusion: The incidence of de novo HPV infections is not significantly different in users of different types of IUD.\",\"PeriodicalId\":13568,\"journal\":{\"name\":\"Infectious Agents and Cancer\",\"volume\":\"20 1\",\"pages\":\"54\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12326846/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Agents and Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13027-025-00688-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Agents and Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13027-025-00688-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：荟萃分析发现使用宫内节育器（IUD）的人宫颈癌发病率较低，但这些研究尚未能够检查宫内节育器类型的影响。本研究的目的是调查新发高危人乳头瘤病毒（HPV）感染与所报告使用避孕方法的关系，特别是不同类型的宫内节育器。方法：纳入2017-2018年HPV检测阴性的国家宫颈癌筛查项目参与者（n = 11,702）。他们随后在2020-2023年的HPV检测结果与他们报告的避孕方法进行了分析。结果：报告使用激素避孕的参与者与未报告使用激素避孕的女性相比，HPV筛查试验阳性的发生率（5.6%）更高(OR 1.29；95% ci 1.01-1.64)。报告使用激素宫内节育器（HIUD）或含铜宫内节育器（CU-IUD）的妇女中HPV发病率无显著差异。在两轮筛查中报告使用相同避孕方法的妇女，无论她们使用哪种避孕方法，HPV发病率都没有显着差异。结论：不同类型宫内节育器使用者的HPV新发感染发生率无显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Incidence of de novo HPV infections in a previous HPV-negative group, related to use of different contraceptive methods: a retrospective cohort study.

查看原文本刊更多论文

Incidence of de novo HPV infections in a previous HPV-negative group, related to use of different contraceptive methods: a retrospective cohort study.

Background: Users of intrauterine devices (IUDs) have been found to have a lower incidence of cervical cancer in meta-analyses, but these studies have not been able to examine the influence of IUD type. The aim of this study is to investigate the incidence of de novo high-risk human papillomavirus (HPV) infections in relation to the reported use of contraceptive methods, with special regard to different types of IUDs.

Methods: A sample of participants in the national screening program for cervical cancer (n = 11,702) with a negative HPV test in 2017-2018 were included. Their subsequent HPV test results in 2020-2023 were analyzed in relation to their reported contraceptive method.

Results: Participants who reported use of hormonal contraception had higher incidence of a positive HPV screening test (5.6%) compared with women with no reported contraception (4.2%) (OR 1.29; 95% CI 1.01-1.64). There was no significant difference in HPV incidence among women who reported use of hormonal IUD (HIUD) or copper-containing IUD (CU-IUD). Women who reported use of the same contraceptive method in both screening rounds showed no significant differences in HPV incidence, regardless of the contraceptive method they had used.

Conclusion: The incidence of de novo HPV infections is not significantly different in users of different types of IUD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Infectious Agents and Cancer ONCOLOGY-IMMUNOLOGY

CiteScore

5.80

自引率

2.70%

发文量

期刊介绍： Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer. The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular: • HPV and anogenital cancers, as well as head and neck cancers; • EBV and Burkitt lymphoma; • HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases; • HHV8 and Kaposi sarcoma; • HTLV and leukemia; • Cancers in Low- and Middle-income countries. The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries. Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.